ClaudiaLOrdonezMD
Pediatric Pulmonology • Boston, MAPediatric Asthma Pulmonology
Clinical Instructor in Pediatrics, Boston Children's Hospital
Are you Dr. Ordonez?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 47 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
300 Longwood Ave
Boston, MA 02115Phone+1 617-355-1900Fax+1 617-730-0084- Is this information wrong?
Summary
- Dr. Claudia Ordonez, MD is a pediatric pulmonologist in Boston, Massachusetts. She is currently licensed to practice medicine in Massachusetts. She is affiliated with Boston Children's Hospital and is a Clinical Instructor in Pediatrics at Boston Children's Hospital.
Education & Training
University of California (San Francisco)Fellowship, Pediatric Pulmonology, 1995 - 1998
Children's Hospital-OaklandResidency, Pediatrics, 1991 - 1994- University of California San Francisco School of MedicineClass of 1991
Certifications & Licensure
MA State Medical License 1998 - 2024
Publications & Presentations
PubMed
- 107 citationsSweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial dataFrank J. Accurso, Fredrick Van Goor, Jiuhong Zha, Anne Stone, Qunming Dong, Claudia L. Ordoñez, Steven M. Rowe, John P. Clancy, Michael W. Konstan, Heather Hoch, Sonya...> ;Journal of Cystic Fibrosis. 2014 Mar 1
- 40 citationsOptimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D-CFTR mutation.Steven M. Rowe, Bo Liu, Aubrey E. Hill, Heather Hathorne, Morty Cohen, John R. Beamer, Frank J. Accurso, Qunming Dong, Claudia L. Ordoñez, Anne Stone, Eric R. Olson, J...> ;Plos One. 2013 Jul 26
- 362 citationsEfficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with a G551D MutationJane C. Davies, Claire E. Wainwright, Gerard J. Canny, Mark A. Chilvers, Michelle S. Howenstine, Anne Munck, Jochen G. Mainz, Sally Rodriguez, Haihong Li, Karl Yen, Cl...> ;American Journal of Respiratory and Critical Care Medicine. 2013 Jun 1
- Join now to see all
Press Mentions
- Keros Therapeutics Appoints Simon Cooper, M.B.B.S. As Chief Medical OfficerAugust 2nd, 2021
Grant Support
- Phase 2 Study Of VX-770 In Cystic Fibrosis Subjectswith G551DFood And Drug Administration2007
- Formula Forified W/ Docosahexaenoic Acid (DHA) In Infants W/ Cystic FibrosisNational Center For Research Resources2006
- Assessment Of Induced Sputum As A Tool To Evaluate Anti-Inflammatory AgentsNational Center For Research Resources2006
- P Aeruginosa Virulence In Cystic Fibrosis Lung DiseaseNational Heart, Lung, And Blood Institute2005–2006
- Use Of Sputum IND To Study Infection &Inflam In Child W/Cf PHS I&IiNational Center For Research Resources2005
- Tissue Bank For Pulmonary DiseasesNational Center For Research Resources2004–2005
- P. Aeruginosa Virulence In Cystic Fibrosis Lung DiseaseNational Heart, Lung, And Blood Institute2004
- Use Of Sputum Ind. To Study Infection &Inflam. In Child. W/C.F. PHS I&IiNational Center For Research Resources2004
- Study Of Airway Inflammation In Subjects With Cystic FibrosisNational Center For Research Resources2004
- Phase I Trial Comparing Two Delivery Methods And Doses Of Tobi In CF PatientsNational Center For Research Resources2004
- Cystic Fibrosis Once Daily Aminoglycoside Clinical Trial (CFODACT)National Center For Research Resources2004
- Free Elastase In BAL Fluid In Cystic Fibrosis PatientsNational Center For Research Resources2000–2002
- Airway Inflammation In Cystic FibrosisNational Center For Research Resources2000–2002
Hospital Affiliations
Boston Children's HospitalBoston, Massachusetts
